| Management target | Revenue 17.0% 1H'26 |
|---|
| Revenue growth | 7% YoY in Q2/2026 |
|---|---|
| Margins | PBT margin improved from 24% to 27% YoY in Q2 |
| Demand visibility | Strong momentum in diabetes segment |
| Management confidence | High |
Growth
Q2'26 total income rose 7% to ₹4,439 Mio; Profit before tax (PBT) grew 19% to ₹1,123 Mio.
Outlook
Diabetes BU achieved 17% growth in H1'26; focus remains on innovative portfolio, public sector expansion, and AI readiness.
Risks
Export sales declined 2% in Q2 and 7% in H1; partnership business faces some headwinds.
Last quarter's promises, checked
Delivered
- Guided 2026 start on good note → delivered 7% revenue & 19% PBT growth (= BEAT)
- Guided diabetes franchise momentum → delivered 14% Q2 growth (= BEAT)
- Guided opex efficiency → delivered PBT margin 24% to 27% (= BEAT)
Partly delivered
- Guided insulin volume acceleration → delivered +6% volume (= PARTIAL)
Missed
- Guided partnership stabilization → delivered 2% growth with headwinds (= MISS)
Investor Presentation filed with NSE, NSE: SANOFI. Summary written with AI assistance from the document.
Sanofi India Ltd: key numbers
- Share price
- ₹3,140.20
- Market cap
- ₹7,232 Cr
- Revenue (annual)
- ₹1,837 Cr
- Net profit (annual)
- ₹326.7 Cr
- P/E (TTM)
- 22.3×Sector 50.4×
- Promoter holding
- 60.40%+0.00% QoQ
- FII holding
- 5.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanofi India Ltd
All →Sanofi India Legal & Regulatory
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
- Value
- ₹23.74 Cr
- From
- Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
- Promoter stake change
- +15.20%
Sanofi India Promoter Selling (Off-Market)
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India Legal & Regulatory
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
- Value
- ₹1.07 Cr
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
- Promoter stake change
- +15.20%
Sanofi India Legal & Regulatory
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.